全文获取类型
收费全文 | 3008篇 |
免费 | 201篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 89篇 |
儿科学 | 107篇 |
妇产科学 | 51篇 |
基础医学 | 336篇 |
口腔科学 | 172篇 |
临床医学 | 421篇 |
内科学 | 636篇 |
皮肤病学 | 18篇 |
神经病学 | 348篇 |
特种医学 | 102篇 |
外科学 | 285篇 |
综合类 | 64篇 |
预防医学 | 250篇 |
眼科学 | 15篇 |
药学 | 204篇 |
肿瘤学 | 129篇 |
出版年
2021年 | 29篇 |
2020年 | 24篇 |
2019年 | 47篇 |
2018年 | 46篇 |
2017年 | 23篇 |
2016年 | 43篇 |
2015年 | 38篇 |
2014年 | 57篇 |
2013年 | 127篇 |
2012年 | 138篇 |
2011年 | 166篇 |
2010年 | 79篇 |
2009年 | 60篇 |
2008年 | 133篇 |
2007年 | 158篇 |
2006年 | 142篇 |
2005年 | 166篇 |
2004年 | 113篇 |
2003年 | 94篇 |
2002年 | 99篇 |
2001年 | 91篇 |
2000年 | 107篇 |
1999年 | 67篇 |
1998年 | 39篇 |
1997年 | 35篇 |
1996年 | 49篇 |
1995年 | 36篇 |
1994年 | 32篇 |
1993年 | 30篇 |
1992年 | 64篇 |
1991年 | 64篇 |
1990年 | 75篇 |
1989年 | 77篇 |
1988年 | 82篇 |
1987年 | 78篇 |
1986年 | 59篇 |
1985年 | 48篇 |
1984年 | 47篇 |
1983年 | 35篇 |
1982年 | 27篇 |
1981年 | 15篇 |
1980年 | 18篇 |
1979年 | 22篇 |
1978年 | 21篇 |
1977年 | 17篇 |
1976年 | 18篇 |
1975年 | 19篇 |
1974年 | 21篇 |
1973年 | 23篇 |
1972年 | 16篇 |
排序方式: 共有3227条查询结果,搜索用时 15 毫秒
51.
A controlled trial of treatment of acquired immunodeficiency in severe measles with thymic humoral factor. 下载免费PDF全文
D W Beatty Z T Handzel M Pecht C R Ryder J Hughes K McCabe N Trainin 《Clinical and experimental immunology》1984,56(3):479-485
A randomized controlled trial of treatment with thymic humoral factor (THF) in 20 children with severe complicated acute measles infection, resulted in objective benefit as evidenced by improvement in the ESR and a fall in C-reactive protein, fewer complications and a reduced incidence of secondary herpes infection. An increased ratio of helper to suppressor T cells (OKT4/OKT8 ratio) and a greater lymphocyte transformation response to phytohaemagglutin was seen in those children receiving THF. We conclude that THF treatment helps to prevent the development of complications particularly secondary viral infections possibly by enhancing cell-mediated immune responses. 相似文献
52.
Chondrocyte-derived apoptotic bodies and calcification of articular cartilage 总被引:17,自引:0,他引:17 下载免费PDF全文
Sanshiro Hashimoto Robert L. Ochs Fred Rosen Jacqueline Quach Greg McCabe Joell Solan J. Edwin Seegmiller Robert Terkeltaub Martin Lotz 《Proceedings of the National Academy of Sciences of the United States of America》1998,95(6):3094-3099
Chondrocytes exposed to nitric oxide (NO) or antibody to Fas undergo cell death by apoptosis. This study examines structural and functional properties of chondrocyte-derived apoptotic bodies. In NO treated cartilage, the dense pericellular matrix that normally surrounds the cells is degraded and apoptotic bodies accumulate within and in the vicinity of the chondrocyte lacunae. Functional analysis shows that apoptotic bodies isolated from NO-treated chondrocytes or cartilage produce pyrophosphate. The levels of pyrophosphate produced by apoptotic bodies are increased by pretreatment of the chondrocytes with transforming growth factor β and decreased by interleukin 1. Apoptotic bodies contain alkaline phosphatase and NTP pyrophosphohydrolase activities and can precipitate calcium. These results suggest that chondrocyte-derived apoptotic bodies express functional properties that may contribute to the pathologic cartilage calcification observed in aging and osteoarthritis. 相似文献
53.
54.
55.
Lina A Ricciardelli David Mellor Marita P McCabe Alexander J Mussap David J Hallford Matthew Tyler 《BMC public health》2012,12(1):28
Background
Overall the physical health of Indigenous men is among the worst in Australia. Research has indicated that modifiable lifestyle factors, such as poor nutrition and physical inactivity, appear to contribute strongly to these poor health conditions. To effectively develop and implement strategies to improve the health of Australia's Indigenous peoples, a greater understanding is needed of how Indigenous men perceive health, and how they view and care for their bodies. Further, a more systematic understanding of how sociocultural factors affect their health attitudes and behaviours is needed. This article presents the study protocol of a community-based investigation into the factors surrounding the health and body image of Indigenous Australian men. 相似文献56.
Giugliano RP Roe MT Harrington RA Gibson CM Zeymer U Van de Werf F Baran KW Hobbach HP Woodlief LH Hannan KL Greenberg S Miller J Kitt MM Strony J McCabe CH Braunwald E Califf RM;INTEGRITI Investigators 《Journal of the American College of Cardiology》2003,41(8):1251-1260
OBJECTIVES: The goal of this study was to evaluate combinations of eptifibatide with reduced-dose tenecteplase (TNK) in ST-elevation myocardial infarction (STEMI). BACKGROUND: Glycoprotein IIb/IIIa inhibitors enhance thrombolysis. The role of combination therapy in clinical practice remains to be established. METHODS: Patients (n = 438) with STEMI <6 h were enrolled. In dose-finding, 189 patients were randomized to different combinations of double-bolus eptifibatide and reduced-dose TNK. In dose-confirmation, 249 patients were randomized 1:1 to eptifibatide 180 microg/kg bolus, 2 microg/kg/min infusion, and 180 microg/kg bolus 10 min later (180/2/180) plus half-dose TNK (0.27 mg/kg) or standard-dose (0.53 mg/kg) TNK monotherapy. All patients received aspirin and unfractionated heparin (60 U/kg bolus; infusion 7 U/kg/h [combination], 12 U/kg/h [monotherapy]). The primary end point was Thrombolysis In Myocardial Infarction (TIMI) grade 3 epicardial flow at 60 min. RESULTS: In dose-finding, TIMI grade 3 flow rates were similar across groups (64% to 68%). Arterial patency was highest for eptifibatide 180/2/180 plus half-dose TNK (96%, p = 0.02 vs. eptifibatide 180/2/90 plus half-dose TNK). In dose-confirmation, this combination, compared with TNK monotherapy, tended to achieve more TIMI 3 flow (59% vs. 49%, p = 0.15), arterial patency (85% vs. 77%, p = 0.17), and ST-segment resolution (median 71% vs. 61%, p = 0.08) but was associated with more major hemorrhage (7.6% vs. 2.5%, p = 0.14) and transfusions (13.4% vs. 4.2%, p = 0.02). Intracranial hemorrhage occurred in 1.0%, 0.6%, and 1.7% of patients treated with any combination, eptifibatide 180/2/180 and half-dose TNK, and TNK monotherapy, respectively. CONCLUSIONS: Double-bolus eptifibatide (180/2/180) plus half-dose TNK tended to improve angiographic flow and ST-segment resolution compared with TNK monotherapy but was associated with more transfusions and non-cerebral bleeding. Further study is needed before this combination can be recommended for general use. 相似文献
57.
Signal transduction by the platelet Fc receptor 总被引:6,自引:1,他引:6
We have evaluated the mechanism by which crosslinking human platelet Fc receptor (FcR) for IgG triggers platelet aggregation and the platelet release reaction. Platelet FcR was crosslinked by incubating purified human platelets with anti-FcRII monoclonal antibody and F(ab')2 anti- mouse Ig. The resultant [Ca2+]i increase, monitored by Fura-2 and measured in the absence of extracellular Ca2+, reached a peak of 750 +/- 50 nmol/L. The effects of cyclooxygenase inhibitors, aspirin and indomethacin, and a phospholipase A2 inhibitor, dibromoacetophenone, were examined. Regardless of the inhibitor, at least 25% of the [Ca2+]i increase remained. Thrombin (0.2 U/mL) stimulated an immediate [Ca2+]i increase that reached 1.95 +/- 0.8 mumol/L. The [Ca2+]i increase generated by thrombin was only slightly reduced by these inhibitors. Crosslinking the FcRII of platelets resulted in a fivefold increase in the production of [3H]inositol phosphates, (IP) which, in the absence of extracellular Ca2+ was insensitive to aspirin. The activation of a [Ca2+]i increase along with the measured increases in IP indicate that FcRII crosslinking leads to the activation of phospholipase C (PLC). In contrast to thrombin, platelet activation via FcRII depends to a large extent on arachidonic acid metabolites. However, neither cyclooxygenase nor phospholipase A2 inhibitors completely blocked FcRII-stimulated [Ca2+]i increase. These observations led us to propose that crosslinking of platelet FcRII initially activates PLC. 相似文献
58.
59.
Jacqueline AM Smith DL Patil OT Daniels Y-S Ding J-D Gallezot S Henry KHS Kim S Kshirsagar WJ Martin GP Obedencio E Stangeland PR Tsuruda W Williams RE Carson ST Patil 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2015,18(2)
Background:
Monoamine reuptake inhibitors exhibit unique clinical profiles that reflect distinct engagement of the central nervous system (CNS) transporters.Methods:
We used a translational strategy, including rodent pharmacokinetic/pharmacodynamic modeling and positron emission tomography (PET) imaging in humans, to establish the transporter profile of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor.Results:
TD-9855 was a potent inhibitor of norepinephrine (NE) and serotonin 5-HT uptake in vitro with an inhibitory selectivity of 4- to 10-fold for NE at human and rat transporters. TD-9855 engaged norepinephrine transporters (NET) and serotonin transporters (SERT) in rat spinal cord, with a plasma EC50 of 11.7ng/mL and 50.8ng/mL, respectively, consistent with modest selectivity for NET in vivo.Accounting for species differences in protein binding, the projected human NET and SERT plasma EC50 values were 5.5ng/mL and 23.9ng/mL, respectively. A single-dose, open-label PET study (4–20mg TD-9855, oral) was conducted in eight healthy males using the radiotracers [11C]-3-amino-4- [2-[(di(methyl)amino)methyl]phenyl]sulfanylbenzonitrile for SERT and [11C]-(S,S)-methylreboxetine for NET. The long pharmacokinetic half-life (30–40h) of TD-9855 allowed for sequential assessment of SERT and NET occupancy in the same subject. The plasma EC50 for NET was estimated to be 1.21ng/mL, and at doses of greater than 4mg the projected steady-state NET occupancy is high (>75%). After a single oral dose of 20mg, SERT occupancy was 25 (±8)% at a plasma level of 6.35ng/mL.Conclusions:
These data establish the CNS penetration and transporter profile of TD-9855 and inform the selection of potential doses for future clinical evaluation. 相似文献60.
Bahira Shahim S. Chris Malaisrie Isaac George Vinod H. Thourani Angelo B. Biviano Mark Russo David L. Brown Vasilis Babaliaros Robert A. Guyton Susheel K. Kodali Tamim M. Nazif Samir Kapadia Philippe Pibarot James M. McCabe Mathew Williams Philippe Genereux Michael Lu Xiao Yu Ioanna Kosmidou 《JACC: Cardiovascular Interventions》2021,14(14):1565-1574
ObjectivesThe aim of this study was to assess the incidence and prognostic impact of early and late postoperative atrial fibrillation or flutter (POAF) in patients with severe aortic stenosis (AS) treated with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR).BackgroundThere is an ongoing controversy regarding the incidence, recurrence rate, and prognostic impact of early (in-hospital) POAF and late (postdischarge) POAF in patients with AS undergoing TAVR or SAVR.MethodsIn the PARTNER (Placement of Aortic Transcatheter Valve) 3 trial, patients with severe AS at low surgical risk were randomized to TAVR or SAVR. Analyses were performed in the as-treated population excluding patients with preexistent atrial fibrillation or flutter.ResultsAmong 781 patients included in the analysis, early POAF occurred in 152 (19.5%) (18 of 415 [4.3%] and 134 of 366 [36.6%] following TAVR and SAVR, respectively). Following discharge, 58 new or recurrent late POAF events occurred within 1 year following the index procedure in 55 of 781 patients (7.0%). Early POAF was not an independent predictor of late POAF following discharge (odds ratio: 1.04; 95% CI: 0.52-2.08; P = 0.90). Following adjustment, early POAF was not an independent predictor of the composite outcome of death, stroke, or rehospitalization (hazard ratio: 1.10; 95% CI: 0.64-1.92; P = 0.72), whereas late POAF was associated with an increased adjusted risk for the composite outcome (hazard ratio: 8.90; 95% CI: 5.02-15.74; P < 0.0001), irrespective of treatment modality.ConclusionsIn the PARTNER 3 trial, early POAF was more frequent following SAVR compared with TAVR. Late POAF, but not early POAF, was significantly associated with worse outcomes at 2 years, irrespective of treatment modality. 相似文献